$DIN

Dine Brands (DIN) Q2 2026 Earnings Call Transcript

Dine Brands Global (DIN) reported Q2 2026 revenue of $240.9 million, up 4.4% year over year, driven mainly by acquiring restaurants from franchisees. Adjusted EBITDA fell to $54.2 million and adjusted diluted EPS was $1.16. IHOP domestic comps rose 1.5%, Applebee’s fell 1.8%. Management maintained full-year 2026 guidance.

Original reporting
Published Aug 12, 2026, 4:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dine Brands (DIN) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$DINNeutralMed
01

Why it matters

Key decision inputs for traders are the direction of margins (commodity cost inflation), cash generation (adjusted free cash flow down), and demand trends (IHOP comps up, Applebee’s comps down but improving sequentially), with guidance held steady.

02

Market read

The transcript supplies concrete Q2 datapoints and cost drivers that can drive near-term sentiment, even though full-year guidance was maintained.

03

What to watch

The transcript highlights a large capex increase and acquisition-driven G&A and profitability drag; traders may be underweighting how much of the cash weakness is timing-related versus structural.

Relevance 7/10Novelty 6/10Timing: post-earnings call transcript, for positioning ahead of next earnings/updates

Background

The piece is a Q2 2026 earnings call transcript for Dine Brands Global, covering Applebee’s and IHOP operating metrics, costs, capital spending, and full-year guidance.

Company-level read

Ticker impact

$DINNeutralMedium confidence
Context

Dine Brands reported Q2 2026 revenue of $240.9M, adjusted EBITDA $54.2M, and maintained full-year 2026 guidance amid higher beef costs.

Expected impact

Near-term volatility likely around margin and free-cash-flow weakness, with guidance support limiting downside.

Evidence & confidence

The article provides multiple concrete datapoints (revenue growth, EBITDA/EPS changes, commodity cost headwinds, capex jump, and AFCF decline) but does not include a new guidance revision or a fresh capital return change beyond the quarter’s disclosed amounts.

Market effects

Restaurant franchisor-operator peers may face similar beef-cost and inflation-driven demand tradeoffs; dual-brand remodel and conversion execution remains a key differentiator.

No explicit regional demand shock; commentary points to broad consumer spending restraint.

Limited, as the disclosed drivers (beef prices, food-away-from-home inflation) are primarily domestic.

Counterpoint

Despite weaker adjusted EBITDA and sharply lower adjusted free cash flow, management’s maintained full-year guidance and IHOP traffic gains could indicate the margin hit is temporary and conversion/remodel spend is front-loaded.

Key entities

  • Dine Brands Global, Inc.

    Operator of Applebee’s and IHOP; reported Q2 2026 results and discussed commodity costs, remodel/conversion pipeline, and full-year guidance.

  • John Peyton

    CEO and President of Applebee’s, cited sequential improvement and guest interaction metrics.

  • Vance Chang

    CFO, discussed commodity cost drivers and profitability/cash impacts from construction and acquisitions.

  • Lawrence Kim

    IHOP President, discussed IHOP same-restaurant sales, off-premise growth, and LTO performance.

Related articles

$DINMed

Dine Brands Global, Inc. Q2 2026 Earnings Call Summary

Dine Brands Global (Applebee’s, IHOP) reported Q2 2026 call updates: management cited intentional consumer spending amid inflation and maintained full-year guidance. Applebee’s saw sequential improvement after a weak April, with remodels lifting mid-single-digit sales. IHOP beat traffic benchmarks for a third quarter. Adjusted FCF fell to $3.7M in H1; $100M buyback authorized.

$DINMed

Dine Brands Global, Inc. (DIN): Results of Operations and Financial Condition

Dine Brands Global, Inc. (DIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d148591dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Investor Contact Matt Lee Sr. Vice President, Finance and Investor Relations Dine Brands Global, Inc. IR@dinebrands.com Media Contact Susan Nelson Sr. Vice President, Global Communications Dine Brands Global, I

$ORGOMed

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.

$CRWVMed

CoreWeave Stock Buy or Sell Debate Intensifies in 2026 After Q2 Beat and $104 Billion Backlog

CoreWeave Inc. shares closed at $105.26 on Aug. 14, 2026 after its Q2 results. Revenue rose to $2.58B from $1.21B a year earlier; adjusted operating income was $128M, but GAAP net loss widened to $626M due to higher interest expense. The company raised 2026 revenue guidance to $12.4B-$13.2B and projected adjusted operating income of $960M-$1.15B. Backlog was about $104B.

$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.